Early-stage Peripheral Non-small Cell Lung Cancer
Conditions
Brief summary
This study aims to learn about the long-term safety and effectiveness of personalized stereotactic body radiotherapy (SBRT) in patients with early-stage peripheral non-small cell lung cancer (NSCLC). Individualized SBRT is a specialized radiation technique that delivers precise, high-dose treatment while minimizing damage to surrounding normal tissues. The main question it aims to answer is: Does individualized SBRT maintain local tumor control and patient survival at 3 years without significant side effects? Patients with early-stage peripheral NSCLC who are medically inoperable or refuse surgery, and who are scheduled to receive individualized SBRT as their standard treatment, will provide the data to assess the safety and efficacy of this personalized radiation approach.
Interventions
DEVICEndividualized Stereotactic Body Radiotherapy (SBRT) System
The individualized SBRT system employs advanced image-guided radiation delivery to deliver highly conformal, ablative doses to early-stage peripheral non-small-cell lung cancer while minimizing exposure to surrounding normal tissues. Treatment is delivered via a state-of-the-art robotic radiosurgery platform (e.g., CyberKnife M6) according to patient-specific fractionation schedules based on tumor size and proximity to critical structures, following standard indications and institutional protocols for medically inoperable or surgically refused cases.
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant or legal guardian provides written informed consent. * Age ≥18 years; no upper age limit; male or female. * Pathologically confirmed non-small-cell lung cancer (NSCLC) staged T1-2N0M0 (IA-IIA, AJCC 8th ed.). * Peripheral tumor location: ≥2 cm from the proximal bronchial tree or any mediastinal structure. * Medically inoperable (e.g., FEV1 \<40 % predicted, DLCO \<40 % predicted, NYHA class III-IV heart failure) or refusal of surgery. * ECOG performance status 0-2. * Life expectancy ≥6 months per investigator judgment. * Measurable disease by RECIST 1.1. * Adequate organ function (blood counts, liver and renal indices) per institutional standards. * Willing and able to comply with all study procedures, imaging schedules, and follow-up visits. * Effective contraception for women of child-bearing potential and fertile men for 12 months after SBRT completion.
Exclusion criteria
* Previous thoracic radiotherapy, chemotherapy, targeted therapy, or surgery for lung cancer. * Evidence of regional or distant metastases. * Concurrent or prior malignancy within 5 years (except adequately treated basal-cell carcinoma of skin or carcinoma in situ of cervix). * Active interstitial pneumonitis, radiation pneumonitis, drug-induced pneumonitis, or clinically significant pulmonary fibrosis. * Pregnancy, lactation, or planned pregnancy. * Participation in another interventional clinical trial with an unmet primary endpoint. * Known psychiatric disorder, substance abuse, or other condition that would impair compliance. * Contraindication to contrast-enhanced CT or PET-CT imaging. * Investigator-determined medical, social, or psychological contraindications that could compromise safety or data integrity.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-year overall survival (OS) | Approximately 36 months after enrollment | Three-year overall survival is defined as the proportion of participants who remain alive at 36 months from the start of individualized stereotactic body radiotherapy (SBRT). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 3-year Progression-Free Survival (PFS) | Enrollment → 36 months | Proportion of participants alive and without radiographic progression at 36 months. |
| 3-year Local Control (LC) | Enrollment → 36 months | Proportion of participants with no evidence of tumor recurrence at the irradiated site at 36 months. |
| Objective Response Rate (ORR) | Enrollment → ~5 months (≈1 month to complete SBRT plus 4 months follow-up) | Percentage of participants achieving complete or partial response per RECIST 1.1 at 4 months after SBRT completion. |
| Adverse Event Incidence | Enrollment → 6 months after last SBRT fraction | Frequency and severity of all treatment-related toxicities graded by CTCAE 5.0, collected continuously. |
Countries
China
Outcome results
None listed